;PMID: 7578214
;source_file_996.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..49] = [t:0..49]
;1)sentence:[e:55..140] = [t:55..140]
;2)section:[e:144..197] = [t:144..197]
;3)section:[e:201..255] = [t:201..255]
;4)sentence:[e:259..366] = [t:259..366]
;5)sentence:[e:367..484] = [t:367..484]
;6)sentence:[e:485..652] = [t:485..652]
;7)sentence:[e:654..764] = [t:654..764]
;8)sentence:[e:765..948] = [t:765..948]
;9)sentence:[e:949..1088] = [t:949..1088]
;10)sentence:[e:1089..1290] = [t:1089..1290]
;11)sentence:[e:1291..1460] = [t:1291..1460]
;12)sentence:[e:1461..1661] = [t:1461..1661]
;13)section:[e:1665..1709] = [t:1665..1709]

;section 0 Span:0..49
;Biochim Biophys Acta. 1995 Oct 10;1231(3):255-64.
(SEC
  (FRAG (NNP:[0..7] Biochim) (NNP:[8..15] Biophys) (NNP:[16..20] Acta)
        (.:[20..21] .) (CD:[22..26] 1995) (NNP:[27..30] Oct)
        (CC:[31..39] 10;1231-LRB-) (CD:[39..40] 3) (-RRB-:[40..41] -RRB-)
        (CD:[41..45] :255) (::[45..46] -) (CD:[46..48] 64) (.:[48..49] .)))

;sentence 1 Span:55..140
;NADPH oxidase activity of cytochrome P-450 BM3 and its constituent reductase 
;domain.
;[55..68]:substance:"NADPH oxidase"
;[81..101]:cyp450:"cytochrome P-450 BM3"
;[122..131]:substance:"reductase"
(SENT
  (NP-HLN
    (NP
      (NML (NN:[55..60] NADPH) (NN:[61..68] oxidase))
      (NN:[69..77] activity))
    (PP (IN:[78..80] of)
      (NP
        (NML (NN:[81..91] cytochrome) (NN:[92..97] P-450))
        (NN:[98..101] BM3)))
    (CC:[102..105] and)
    (NP (PRP$:[106..109] its) (JJ:[110..121] constituent)
        (NN:[122..131] reductase) (NN:[133..139] domain))
    (.:[139..140] .)))

;section 2 Span:144..197
;Munro AW, Lindsay JG, Coggins JR, Kelly SM, Price NC.
(SEC
  (FRAG (NNP:[144..149] Munro) (NNP:[150..152] AW) (,:[152..153] ,)
        (NNP:[154..161] Lindsay) (NNP:[162..164] JG) (,:[164..165] ,)
        (NNP:[166..173] Coggins) (NNP:[174..176] JR) (,:[176..177] ,)
        (NNP:[178..183] Kelly) (NNP:[184..186] SM) (,:[186..187] ,)
        (NNP:[188..193] Price) (NNP:[194..197] NC.)))

;section 3 Span:201..255
;Department of Biochemistry, University of Glasgow, UK.
(SEC
  (FRAG (NNP:[201..211] Department) (IN:[212..214] of)
        (NNP:[215..227] Biochemistry) (,:[227..228] ,)
        (NNP:[229..239] University) (IN:[240..242] of) (NNP:[243..250] Glasgow)
        (,:[250..251] ,) (NNP:[252..255] UK.)))

;sentence 4 Span:259..366
;Cytochrome P-450 BM3 from Bacillus megaterium catalyses NADPH oxidation in
;the  absence of added substrate.
;[259..279]:cyp450:"Cytochrome P-450 BM3"
;[315..320]:substance:"NADPH"
;[356..365]:substance:"substrate"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (NN:[259..269] Cytochrome) (NN:[270..275] P-450))
        (NN:[276..279] BM3))
      (PP (IN:[280..284] from)
        (NP (NNP:[285..293] Bacillus) (NNP:[294..304] megaterium))))
    (VP (VBZ:[305..314] catalyses)
      (NP (NN:[315..320] NADPH) (NN:[321..330] oxidation))
      (PP (IN:[331..333] in)
        (NP
          (NP (DT:[334..337] the) (NN:[339..346] absence))
          (PP (IN:[347..349] of)
            (NP (VBN:[350..355] added) (NN:[356..365] substrate))))))
    (.:[365..366] .)))

;sentence 5 Span:367..484
;This activity is also associated with the  independently expressed
;flavin-containing reductase domain of the protein.
;[434..461]:substance:"flavin-containing reductase"
;[476..483]:substance:"protein"
(SENT
  (S
    (NP-SBJ-1 (DT:[367..371] This) (NN:[372..380] activity))
    (VP (VBZ:[381..383] is)
      (ADVP (RB:[384..388] also))
      (VP (VBN:[389..399] associated)
        (NP-1 (-NONE-:[399..399] *))
        (PP-CLR (IN:[400..404] with)
          (NP
            (NP (DT:[405..408] the)
              (ADJP (RB:[410..423] independently) (VBN:[424..433] expressed))
              
              (ADJP (NN:[434..440] flavin) (HYPH:[440..441] -)
                    (VBG:[441..451] containing))
              (NN:[452..461] reductase)
              (NN:[462..468] domain))
            (PP (IN:[469..471] of)
              (NP (DT:[472..475] the) (NN:[476..483] protein)))))))
    (.:[483..484] .)))

;sentence 6 Span:485..652
;The  rates of these activities are more than two orders of magnitude lower
;than those  in the presence of fatty acid P-450 substrates or artificial
;electron acceptors.
;[520..553]:quantitative-value:"more than two orders of magnitude"
;[591..601]:substance:"fatty acid"
;[602..607]:cyp450:"P-450"
;[608..618]:substance:"substrates"
;[622..651]:substance:"artificial electron acceptors"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[485..488] The) (NNS:[490..495] rates))
      (PP (IN:[496..498] of)
        (NP (DT:[499..504] these) (NNS:[505..515] activities))))
    (VP (VBP:[516..519] are)
      (ADJP-PRD
        (ADJP
          (NML
            (NML
              (QP (RBR:[520..524] more) (IN:[525..529] than) (CD:[530..533] two))
              (NNS:[534..540] orders))
            (PP (IN:[541..543] of)
              (NP (NN:[544..553] magnitude))))
          (JJR:[554..559] lower))
        (PP (IN:[560..564] than)
          (NP
            (NP (DT:[565..570] those))
            (PP (IN:[572..574] in)
              (NP
                (NP (DT:[575..578] the) (NN:[579..587] presence))
                (PP (IN:[588..590] of)
                  (NP
                    (NP
                      (NML (JJ:[591..596] fatty) (NN:[597..601] acid))
                      (NN:[602..607] P-450) (NNS:[608..618] substrates))
                    (CC:[619..621] or)
                    (NP (JJ:[622..632] artificial) (NN:[633..641] electron)
                        (NNS:[642..651] acceptors))))))))))
    (.:[651..652] .)))

;sentence 7 Span:654..764
;Electrons derived from NADPH in this fashion are transferred onto oxygen, 
;generating superoxide (O2-) anions.
;[677..682]:substance:"NADPH"
;[720..726]:substance:"oxygen"
;[740..763]:substance:"superoxide (O2-) anions"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[654..663] Electrons))
      (VP (VBN:[664..671] derived)
        (NP (-NONE-:[671..671] *))
        (PP-CLR (IN:[672..676] from)
          (NP (NN:[677..682] NADPH)))
        (PP (IN:[683..685] in)
          (NP (DT:[686..690] this) (NN:[691..698] fashion)))))
    (VP (VBP:[699..702] are)
      (VP (VBN:[703..714] transferred)
        (NP-1 (-NONE-:[714..714] *))
        (PP (IN:[715..719] onto)
          (NP (NN:[720..726] oxygen)))
        (,:[726..727] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[727..727] *))
          (VP (VBG:[729..739] generating)
            (NP
              (NML
                (NML (NN:[740..750] superoxide))
                (NML (-LRB-:[751..752] -LRB-) (NN:[752..754] O2)
                     (SYM:[754..755] -) (-RRB-:[755..756] -RRB-)))
              (NNS:[757..763] anions))))))
    (.:[763..764] .)))

;sentence 8 Span:765..948
;The formation of these active oxygen species  is detectable by luminometry
;and the chemiluminescence can be inhibited through  the addition of
;superoxide dismutase (but not catalase).
;[795..809]:substance:"oxygen species"
;[908..928]:substance:"superoxide dismutase"
;[938..946]:substance:"catalase"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[765..768] The) (NN:[769..778] formation))
        (PP (IN:[779..781] of)
          (NP (DT:[782..787] these) (JJ:[788..794] active)
             (NN:[795..801] oxygen) (NNS:[802..809] species))))
      (VP (VBZ:[811..813] is)
        (ADJP-PRD (JJ:[814..824] detectable)
          (PP (IN:[825..827] by)
            (NP (NN:[828..839] luminometry))))))
    (CC:[840..843] and)
    (S
      (NP-SBJ-1 (DT:[844..847] the) (NN:[848..865] chemiluminescence))
      (VP (MD:[866..869] can)
        (VP (VB:[870..872] be)
          (VP (VBN:[873..882] inhibited)
            (NP-1 (-NONE-:[882..882] *))
            (PP-MNR (IN:[883..890] through)
              (NP
                (NP (DT:[892..895] the) (NN:[896..904] addition))
                (PP (IN:[905..907] of)
                  (NP (NN:[908..918] superoxide) (NN:[919..928] dismutase)))))
            (PRN (-LRB-:[929..930] -LRB-)
              (FRAG (CC:[930..933] but) (RB:[934..937] not)
                (NP (NN:[938..946] catalase)))
              (-RRB-:[946..947] -RRB-))))))
    (.:[947..948] .)))

;sentence 9 Span:949..1088
;This activity is  reminiscent of the microbicidal NADPH oxidase activity
;associated with  neutrophils and other leukocyte blood cell types.
;[986..1012]:substance:"microbicidal NADPH oxidase"
(SENT
  (S
    (NP-SBJ (DT:[949..953] This) (NN:[954..962] activity))
    (VP (VBZ:[963..965] is)
      (ADJP-PRD (JJ:[967..978] reminiscent)
        (PP (IN:[979..981] of)
          (NP
            (NP (DT:[982..985] the)
               (JJ:[986..998] microbicidal)
              (NML (NN:[999..1004] NADPH) (NN:[1005..1012] oxidase))
              (NN:[1013..1021] activity))
            (VP (VBN:[1022..1032] associated)
              (NP (-NONE-:[1032..1032] *))
              (PP-CLR (IN:[1033..1037] with)
                (NP
                  (NP (NNS:[1039..1050] neutrophils))
                  (CC:[1051..1054] and)
                  (NP (JJ:[1055..1060] other) (NN:[1061..1070] leukocyte)
                    (NML (NN:[1071..1076] blood) (NN:[1077..1081] cell))
                    (NNS:[1082..1087] types)))))))))
    (.:[1087..1088] .)))

;sentence 10 Span:1089..1290
;Diphenyliodonium, a potent  inhibitor of the neutrophil NADPH oxidase,
;effectively inhibits fatty acid  hydroxylase and electron transferase
;activities catalysed by P-450 BM3 and its  reductase domain.
;[1089..1105]:substance:"Diphenyliodonium"
;[1117..1126]:substance:"inhibitor"
;[1145..1158]:substance:"NADPH oxidase"
;[1181..1204]:substance:"fatty acid  hydroxylase"
;[1209..1229]:substance:"electron transferase"
;[1254..1263]:cyp450:"P-450 BM3"
;[1273..1282]:substance:"reductase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1089..1105] Diphenyliodonium))
      (,:[1105..1106] ,)
      (NP
        (NP (DT:[1107..1108] a) (JJ:[1109..1115] potent)
            (NN:[1117..1126] inhibitor))
        (PP (IN:[1127..1129] of)
          (NP (DT:[1130..1133] the) (NN:[1134..1144] neutrophil)
             (NN:[1145..1150] NADPH) (NN:[1151..1158] oxidase)))))
    (,:[1158..1159] ,)
    (ADVP (RB:[1160..1171] effectively))
    (VP (VBZ:[1172..1180] inhibits)
      (NP
        (NP
          (NP
            (NML
              (NML (JJ:[1181..1186] fatty) (NN:[1187..1191] acid))
              (NN:[1193..1204] hydroxylase))
            (NML-1 (-NONE-:[1204..1204] *P*)))
          (CC:[1205..1208] and)
          (NML
            (NML (NN:[1209..1217] electron) (NN:[1218..1229] transferase))
            (NML-1 (NNS:[1230..1240] activities))))
        (VP (VBN:[1241..1250] catalysed)
          (NP (-NONE-:[1250..1250] *))
          (PP (IN:[1251..1253] by)
            (NP-LGS
              (NP (NN:[1254..1259] P-450) (NN:[1260..1263] BM3))
              (CC:[1264..1267] and)
              (NP (PRP$:[1268..1271] its) (NN:[1273..1282] reductase)
                  (NN:[1283..1289] domain)))))))
    (.:[1289..1290] .)))

;sentence 11 Span:1291..1460
;CD studies on the native and NADPH-reduced P-450 BM3 and BM3  reductase
;indicate that no secondary structural alteration is caused by  pre-incubation
;with the reductant.
;[1320..1343]:cyp450:"NADPH-reduced P-450 BM3"
;[1348..1362]:substance:"BM3  reductase"
;[1450..1459]:substance:"reductant"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1291..1293] CD) (NNS:[1294..1301] studies))
      (PP (IN:[1302..1304] on)
        (NP (DT:[1305..1308] the)
          (NML
            (NML (JJ:[1309..1315] native)
              (NML-3 (-NONE-:[1315..1315] *P*)))
            (CC:[1316..1319] and)
            (NML
              (ADJP (NN:[1320..1325] NADPH) (HYPH:[1325..1326] -)
                    (VBN:[1326..1333] reduced))
              (NML-3
                (NML
                  (NML-1 (NN:[1334..1339] P-450))
                  (NN:[1340..1343] BM3))
                (CC:[1344..1347] and)
                (NML
                  (NML
                    (NML-1 (-NONE-:[1347..1347] *P*))
                    (NN:[1348..1351] BM3))
                  (NN:[1353..1362] reductase))))))))
    (VP (VBP:[1363..1371] indicate)
      (SBAR (IN:[1372..1376] that)
        (S
          (NP-SBJ-4 (DT:[1377..1379] no) (JJ:[1380..1389] secondary)
                    (JJ:[1390..1400] structural) (NN:[1401..1411] alteration))
          (VP (VBZ:[1412..1414] is)
            (VP (VBN:[1415..1421] caused)
              (NP-4 (-NONE-:[1421..1421] *))
              (PP (IN:[1422..1424] by)
                (NP-LGS
                  (NP (AFX:[1426..1429] pre) (HYPH:[1429..1430] -)
                      (NN:[1430..1440] incubation))
                  (PP (IN:[1441..1445] with)
                    (NP (DT:[1446..1449] the) (NN:[1450..1459] reductant))))))))))
    (.:[1459..1460] .)))

;sentence 12 Span:1461..1661
;Therefore, the previously recognised  reversible time-dependent inactivation
;of P-450 BM3 by NADPH may be attributed  to the NADPH oxidase activity
;associated with the reductase domain of the  enzyme.
;[1541..1550]:cyp450:"P-450 BM3"
;[1554..1559]:substance:"NADPH"
;[1586..1599]:substance:"NADPH oxidase"
;[1629..1638]:substance:"reductase"
;[1654..1660]:substance:"enzyme"
(SENT
  (S
    (ADVP (RB:[1461..1470] Therefore))
    (,:[1470..1471] ,)
    (NP-SBJ-1
      (NP (DT:[1472..1475] the)
        (ADJP (RB:[1476..1486] previously) (VBN:[1487..1497] recognised))
        (JJ:[1499..1509] reversible)
        (ADJP (NN:[1510..1514] time) (HYPH:[1514..1515] -)
              (JJ:[1515..1524] dependent))
        (NN:[1525..1537] inactivation))
      (PP (IN:[1538..1540] of)
        (NP (NN:[1541..1546] P-450) (NN:[1547..1550] BM3)))
      (PP (IN:[1551..1553] by)
        (NP (NN:[1554..1559] NADPH))))
    (VP (MD:[1560..1563] may)
      (VP (VB:[1564..1566] be)
        (VP (VBN:[1567..1577] attributed)
          (NP-1 (-NONE-:[1577..1577] *))
          (PP-CLR (TO:[1579..1581] to)
            (NP
              (NP (DT:[1582..1585] the)
                 (NN:[1586..1591] NADPH) (NN:[1592..1599] oxidase)
                (NN:[1600..1608] activity))
              (VP (VBN:[1609..1619] associated)
                (NP (-NONE-:[1619..1619] *))
                (PP-CLR (IN:[1620..1624] with)
                  (NP
                    (NP (DT:[1625..1628] the) (NN:[1629..1638] reductase)
                        (NN:[1639..1645] domain))
                    (PP (IN:[1646..1648] of)
                      (NP (DT:[1649..1652] the) (NN:[1654..1660] enzyme)))))))))))
    (.:[1660..1661] .)))

;section 13 Span:1665..1709
;PMID: 7578214 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1665..1669] PMID) (::[1669..1670] :) (CD:[1671..1678] 7578214)
        (NN:[1679..1680] -LSB-) (NNP:[1680..1686] PubMed) (::[1687..1688] -)
        (NN:[1689..1696] indexed) (IN:[1697..1700] for)
        (NNP:[1701..1709] MEDLINE-RSB-)))
